trending Market Intelligence /marketintelligence/en/news-insights/trending/6xejsl29b0o3zbaq25uupa2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Mast Therapeutics lays off staff

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Mast Therapeutics lays off staff

Mast Therapeutics Inc. laid off some of its employees as part of a cost-cutting measure.

The restructuring is meant to return focus to AIR001, a clinical-stage investigational drug for treating patients with heart failure as a result of preserved ejection fraction.

Mast Therapeutics is exploring opportunities to monetize its Vepoloxamer programs so it could advance AIR001 instead. Vepoloxamer itself is meant to be used in the sickle cell disease and heart failure.